MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceutical Drug Discovery & Development (Miscellaneous)
AuraSense Therapeutics
Parents
*Architects: BioPharmaceutical Drug Discovery & Development (Miscellaneous)
Companies: Merger Partners_(M&A)
Organization & Developments: Exicure
Children
*Biopharmaceutical company commercializing spherical nucleic acid (SNA) constructs as gene regulation- and chemo-therapeutics for a variety of diseases, including applications in oncology, dermatology, neurology, and for cardiovascular disorders
*Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
*Exicure is Formerly Known as AuraSense Therapeuticsis.
*SNA technology overcomes the most difficult obstacles to gene regulation: genetic targeting with safe and effective in vivo performance.
2011: AuraSense Therapeutics Secures Series B Equity Investment (2011)
3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs.
Craig Mundie, Chief Research and Strategy Officer of Microsoft.
David Walt, co-founder of Illumina
Eric Schmidt, KBE, Former CEO & Chairman of Google, Executive Chairman and CEO of Relativity Space, Philanthropist (2025)
Founded 2009
Investors included Abbott Biotech Ventures, a subsidiary of Abbott. Other key individual investors included Patrick Ryan, founder of Aon
Jumps
Abbott Laboratories (NYSE:ABT)